NCT07033845 Pharmacokinetic Study of Topical Phenylephrine
| NCT ID | NCT07033845 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Applied Biology, Inc. |
| Condition | Chemotherapy Induced Alopecia |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2025-10-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-06-30 with a primary completion date of 2025-10-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pharmacokinetic Study of Topical Phenylephrine
Eligibility Criteria
Inclusion Criteria: * Healthy females, age 18-55 * BMI: 18-30 kg/m² * Fitzpatrick Skin Types I-IV (to standardize absorption risk) * Scalp free from irritation, dermatologic disease, or damage * Able to refrain from using other topical scalp products Exclusion Criteria: * History of cardiovascular disease, hypertension, or arrhythmia * Scalp infections, wounds, or significant hair loss * Recent use of medications that interfere with CYP enzymes or adrenergic systems * Known sensitivity to phenylephrine or ethanol * Positive drug screen or abnormal ECG at screening
Contact & Investigator
Andy Goren, MD
STUDY DIRECTOR
University of Rome G. Marconi
Frequently Asked Questions
Who can join the NCT07033845 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Chemotherapy Induced Alopecia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07033845 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07033845 currently recruiting?
Yes, NCT07033845 is actively recruiting participants. Contact the research team at clinicalstudies@appliedbiology.com for enrollment information.
Where is the NCT07033845 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT07033845 clinical trial?
NCT07033845 is sponsored by Applied Biology, Inc.. The principal investigator is Andy Goren, MD at University of Rome G. Marconi. The trial plans to enroll 24 participants.